CoChat
Sign Up
Cited by 190Diabetes Treatment and ManagementDiabetes Management and ResearchPharmacology and Obesity Treatment

Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis

Deacon, C. F., Mannucci, E., Ahrén, B.·2012·Diabetes, Obesity and Metabolism
DOI 10.1111/j.1463-1326.2012.01603.x
Open this paper in CoChat — free account

Abstract

Aims: During recent years, two strategies of incretin‐based therapy [glucagon‐like peptide‐1 (GLP‐1) receptor agonism and dipeptidyl peptidase‐4 (DPP‐4) inhibition] have entered the market for pharmacological management of type 2 diabetes. A main indication for this therapy is as add‐on to on‐going metformin therapy in subjects with type 2 diabetes who have insufficient glycaemic control with metformin alone. The aim of this study was to compare improvements in glycaemic control and changes in body weight, as well as adverse events, in comparable studies with incretin‐based therapy as add‐on to metformin. Methods: Studies having a duration of 16–30 weeks were identified from PubMed. Results: A total of 27 study groups in 21 studies fulfilled the criteria of examining incretin‐based therapy as add‐on to metformin at clinically recommended doses in patients with type 2 diabetes for 16–30 weeks; 7 of these used a short‐acting GLP‐1 receptor agonist (exenatide BID), 7 used longer acting GLP‐1 receptor agonists (liraglutide or exenatide LAR), whereas 14 studies examined DPP‐4 inhibitors. In all studies, incretin‐based therapy reduced HbA1c concentrations. The reduction in HbA1c was significantly greater in study groups with long‐acting GLP‐1 receptor agonists than with the other two groups (both p < 0.001), whereas there were no differences between exenatide BID and DPP‐4 inhibitors. Across all study groups, there was a negative linear correlation between baseline HbA1c and change in HbA1c (r = −0.70; p < 0.001). Fasting glucose also fell significantly more in study groups given liraglutide or exenatide LAR than in those given exenatide BID or DPP‐4 inhibitors (both p < 0.001). Furthermore, body weight was reduced by a similar extent in the two groups with GLP‐1 receptor agonists and was not significantly altered in the groups with DPP‐4 inhibitors. Lipids, blood pressure and heart rate were not reported consistently, which did not allow general conclusions. Adverse events were rare, apart from increased incidence of nausea and vomiting with GLP‐1 receptor agonists. Conclusion: Incretin‐based therapy efficiently improves glycaemia when added to metformin in patients with type 2 diabetes, and within 16–30 weeks there is a more pronounced reduction in HbA1c with long‐acting GLP‐1 receptor agonists (liraglutide and exenatide LAR) than with exenatide BID and DPP‐4 inhibitors, although the magnitude of the effect is dependent on the baseline values. Both strategies appear to be associated with a very low risk of adverse events, including hypoglycaemia. Finally, the injectable GLP‐1 receptor agonists also reduce body weight (whereas the DPP‐4 inhibitors are weight neutral) but are also associated with a greater incidence of gastrointestinal side effects and a tendency to increase heart rate.

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2012.01603.x

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Long-acting GLP-1 receptor agonists reduced HbA1c and fasting glucose levels to a greater extent than other incretin-based therapies when added to metformin.

    “Long-acting GLP-1 receptor agonists reduced HbA1c and fasting glucose levels to a greater extent than the other therapies [42].”

    From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [42]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Deacon, C. F., Mannucci, E., & Ahrén, B.
Affiliations
  • University of Copenhagen (DK)
  • Azienda Ospedaliero-Universitaria Careggi (IT)
ORCID
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2012-04-24
Volume
14
Issue
8
Pages
762-767
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
DOI
10.1111/j.1463-1326.2012.01603.x
OpenAlex
W2058514432
Cited by
190
References
44
Citations by year
2026: 2 · 2025: 5 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 7 · 2020: 6 · 2019: 8 · 2018: 17 · 2017: 12 · 2016: 16 · 2015: 15 · 2014: 37 · 2013: 37 · 2012: 8
FWCI
4.31
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Diabetes Obesity and Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
type 2 diabetes, GLP-1 receptor agonists, DPP-4 inhibitors, incretin-based therapy, glycemic control, HbA1c, fasting blood glucose, body weight, exenatide, liraglutide, adverse events, heart rate, cost-effectiveness
MeSH terms
Glucagon-Like Peptide-1 Receptor, Sitagliptin Phosphate, Liraglutide, Exenatide, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fasting, Female, Humans, Hypoglycemic Agents, Male, Peptides, Pyrazines, Triazoles, Venoms, Treatment Outcome, Receptors, Glucagon, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review